Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
J Infect Dis. 2017 Sep 15;216(suppl_4):S575-S580. doi: 10.1093/infdis/jix065.
Human infections with novel influenza A viruses are of global public health concern, and antiviral medications have a potentially important role in treatment and prevention of human illness. Initial guidance was developed by the U.S. Centers for Disease Control and Prevention after the emergence of human infections with avian influenza A(H5N1) and has evolved over time, with identification of influenza A(H7N9) virus infections in humans, as well as detection of avian influenza viruses in birds in the United States. This commentary describes the historical context and current guidance for the use of influenza antiviral medications for treatment and post-exposure chemoprophylaxis of human infections with novel influenza A viruses associated with severe human illness, or with the potential to cause severe human disease, and provides the scientific rationale behind current recommendations.
新型甲型流感病毒感染对全球公共卫生具有重要影响,抗病毒药物在治疗和预防人类疾病方面具有潜在的重要作用。美国疾病控制与预防中心在出现人感染甲型禽流感(H5N1)后制定了初步指导意见,并随着时间的推移不断发展,包括人类感染甲型禽流感(H7N9)病毒以及在美国鸟类中检测到禽流感病毒的情况。本评论描述了历史背景和目前使用流感抗病毒药物治疗和暴露后化学预防与严重人类疾病相关或有可能导致严重人类疾病的新型甲型流感病毒感染的指导原则,并提供了当前建议背后的科学依据。